The CASP 16 Experimental Protein–Ligand Datasets
Proteins: Structure, Function, and Bioinformatics · 2026
DOI: 10.1002/prot.70053 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proteins: Structure, Function, and Bioinformatics, 2026. Verfasst von Andreas Tosstorff und 11 weiteren Autor:innen. Beteiligte Einrichtung: Roche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland. Hauptthemen laut MEDLINE: Computational Biology, Coronavirus 3C Proteases, Drug Discovery. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
This paper presents the experimental protein–ligand datasets used as benchmarks in the CASP 16 blind prediction experiment—the first CASP round to incorporate targets from pharmaceutical discovery projects. We have assembled and characterized protein‐ligand complexes for four proteins that are known or candidate drug targets: human chymase, human cathepsin G, human autotaxin, and the SARS‐CoV‐2 main protease. The collection encompasses over 200 co‐crystal structures at resolutions better than 2.7 Å, paired with binding affinity measurements for approximately 160 compounds covering a broad affinity range (nanomolar to high micromolar). These data enabled the CASP16 pose‐prediction and affinity‐prediction challenges. Many systems feature potentially challenging characteristics, including chymase's electropositive surface and acidic ligands, which require proper handling of titratable ligand groups; autotaxin complexes with and without zinc coordination; and a SARS‐CoV‐2 protease crystal form exhibiting an unusually open active site conformation. We describe the experimental approaches—from protein production and crystallization to binding assay development—that yielded these reference data. Contributed by scientists at F. Hoffmann‐La Roche and Idorsia Pharmaceuticals, these datasets represent actual drug discovery projects and therefore provide a realistic testbed for assessing how computational methods perform on pharmaceutically relevant targets. An accompanying paper in the present special journal issue provides a comprehensive assessment of the pose and affinity predictions for these pharmaceutical protein‐ligand systems.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Roche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
- Swiss Light Source, Paul Scherrer Institute, Villigen, Switzerland.
- Idorsia Pharmaceuticals Ltd., Translational Sciences, Allschwil, Switzerland.
- UCB Biopharma SRL, Braine-l'Alleud, Belgium.
- Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California san Diego, La Jolla, California, USA.
ORCID-Profile: Andreas Tosstorff, Markus G Rudolph, Jörg Benz, Bernd Kuhn, Christian Kramer, May Sharpe, Chia-Ying Huang, Alexander Metz, Julien Hazemann, Daniel Ritz, Aengus Mac Sweeney, Michael K Gilson
Zitieren
APA
Tosstorff, A., Rudolph, M. G., Benz, J., Kuhn, B., Kramer, C., Sharpe, M., Huang, C. Y., Metz, A., Hazemann, J., Ritz, D., Sweeney, A. M., & Gilson, M. K. (2026). The CASP 16 Experimental Protein–Ligand Datasets. Proteins: Structure, Function, and Bioinformatics. https://doi.org/10.1002/prot.70053
Vancouver
Tosstorff A, Rudolph MG, Benz J, Kuhn B, Kramer C, Sharpe M, et al. The CASP 16 Experimental Protein–Ligand Datasets. Proteins: Structure, Function, and Bioinformatics. 2026. doi:10.1002/prot.70053
BibTeX
@article{Tosstorff2026,
author = {Tosstorff, Andreas and Rudolph, Markus G and Benz, Jörg and Kuhn, Bernd and Kramer, Christian and Sharpe, May and Huang, Chia-Ying and Metz, Alexander and Hazemann, Julien and Ritz, Daniel and Sweeney, Aengus Mac and Gilson, Michael K},
title = {The CASP 16 Experimental Protein–Ligand Datasets},
journal = {Proteins: Structure, Function, and Bioinformatics},
year = {2026},
doi = {10.1002/prot.70053}
}
EUVIMED